Expanded Label for IV Antibiotic Daptomycin
Cubist Pharmaceuticals has announced the FDA’s approval of its supplemental New Drug Application for daptomycin for injection (Cubicin) as once-a-day therapy at 6 mg/kg for the treatment of Staphylococcus aureus (S. aureus) bloodstream infections, including right-sided endocarditis caused by methicillin-susceptible S. au-reus (MSSA) and methicillin-resistant S. aureus (MRSA). Cubist estimates that these infections account for [...]
Read User's Comments